The collaboration will automate manufacturing of Sonoma’s Phase 1 engineered regulatory T-cell therapy using Cellares’ automated Cell Shuttle platform.
The approval allows segmented production of antibody-drug conjugates at the CDMO’s Hangzhou facility following a joint inspection by three provincial regulators.
